GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake (GASOLIN)
Primary Purpose
Obesity, Adiposity, Type 2 Diabetes
Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
IIGI+GIP
IIGI+GLP-1
IIGI+NaCl (placebo)
OGTT
IIGI+GIP+GLP-1
Sponsored by

About this trial
This is an interventional basic science trial for Obesity focused on measuring incretin hormones, GIP, GLP-1
Eligibility Criteria
Inclusion Criteria:
- Caucasian men
- Age between 25 and 70 years
- Body mass index (BMI) between 25 and 40 kg/m2
Exclusion Criteria:
- Diabetes or prediabetes (defined as glycated haemoglobin (HbA1c) ≥ 43 mmol/mol)
- Anaemia (defined as haemoglobin < 8.3 mmol/l)
- Any gastrointestinal disease that may interfere with the endpoint variables
- Anorexia, bulimia or binge eating disorder
- Allergy or intolerance to ingredients included in the standardised meals
- Tobacco smoking
- Any regular drug treatment that cannot be discontinued for minimum 18 hours
- Any physical or psychological condition that the investigator feels would interfere with trial participation
Sites / Locations
- Center for Diabetesresearch, Gentofte hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm Type
Active Comparator
Active Comparator
Placebo Comparator
Active Comparator
Other
Arm Label
IIGI+GIP
IIGI+GLP-1
IIGI+NaCl (placebo)
IIGI+GIP+GLP-1
50 g OGTT
Arm Description
4 hour i.v. infusion of glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemic conditions
4 hour i.v. infusion of glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemic conditions
4 hour i.v. NaCl (placebo) during isoglycemic conditions
4 hour co-infusion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1
50 g oral glucose tolerance test (OGTT)
Outcomes
Primary Outcome Measures
food intake
How much does the participant eat of from the ad libitum meal, measured in gram
Secondary Outcome Measures
hunger
feeling of hunger measured on a visual analogue scale
satiety
feeling of satiety measured on a visual analogue scale
Fullness
feeling of fullness measured on a visual analogue scale
Prospective food consumption
Prospective food consumption measured on a visual analogue scale
resting energy expenditure (REE)
changes in REE measured by a ventilated hood 15 minutes at baseline and 15 minutes at time point 210 min.
Insulin
changes in insulin measured in serum
C-peptide level
changes in C-peptide level measured in serum
glucagon levels
changes in glucagon levels measured in plasma
Cholesterol and FFA
changes in cholesterol (TAG, Total cholesterol and free fatty acid measured in plasma)
C-terminal cross-linked telopeptide of bone collagen (CTX)
changes in level of CTX measured in plasma
procollagen type 1 N-terminal propeptide (P1NP)
changes in level of P1NP measured in plasma
Full Information
NCT ID
NCT02598791
First Posted
October 31, 2015
Last Updated
December 4, 2018
Sponsor
University Hospital, Gentofte, Copenhagen
1. Study Identification
Unique Protocol Identification Number
NCT02598791
Brief Title
GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake
Acronym
GASOLIN
Official Title
GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake
Study Type
Interventional
2. Study Status
Record Verification Date
December 2018
Overall Recruitment Status
Completed
Study Start Date
October 1, 2015 (Actual)
Primary Completion Date
June 20, 2016 (Actual)
Study Completion Date
June 20, 2016 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital, Gentofte, Copenhagen
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
We aim to delineate the effects of separate and combined infusion of GIP and GLP-1 on food intake, appetite, bone health and fat metabolism in overweight/obese subjects.
Detailed Description
The gut-derived incretin glucagon-like peptide-1 (GLP-1) is a potent regulator of gastric emptying, appetite and food intake in humans whereas its sister incretin hormone, glucose-dependent insulinotropic polypeptide (GIP), does not seem to have independent effects on these variables in humans. Interestingly, recent data from rodents have shown that concomitant activation of the GIP and the GLP-1 receptor may potentiate the satiety-promoting and body weight-reducing effects of GLP-1. Also, evidence suggests that GIP may be an important mediator of bone remodelling and lipid deposition. The effect of simultaneous activation of the GIP and GLP-1 receptors on appetite, food intake, fat metabolism and bone health has not been thoroughly examined in humans. The aim of this study is to delineate the effects of GIP/GLP-1 receptor co-activation on food intake, mechanisms regulating food intake, fat and bone metabolism in obese subjects.
Material and methods:
The investigators plan to include 18 obese/overweight men without diabetes. The primary endpoint of the study is food intake during continuous intravenous infusions of saline (placebo), GIP, GLP-1 and GIP+GLP-1, respectively. Secondary endpoints includes resting energy expenditure (measured by indirect calorimetry), appetite, satiety and hunger assessments (measured by visual analogue scales), plasma insulin, C-peptide and glucagon secretion, plasma triglycerides, cholesterols, and free fatty acid responses and changes in plasma bone turnover markers.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Adiposity, Type 2 Diabetes
Keywords
incretin hormones, GIP, GLP-1
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
18 (Actual)
8. Arms, Groups, and Interventions
Arm Title
IIGI+GIP
Arm Type
Active Comparator
Arm Description
4 hour i.v. infusion of glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemic conditions
Arm Title
IIGI+GLP-1
Arm Type
Active Comparator
Arm Description
4 hour i.v. infusion of glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemic conditions
Arm Title
IIGI+NaCl (placebo)
Arm Type
Placebo Comparator
Arm Description
4 hour i.v. NaCl (placebo) during isoglycemic conditions
Arm Title
IIGI+GIP+GLP-1
Arm Type
Active Comparator
Arm Description
4 hour co-infusion of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1
Arm Title
50 g OGTT
Arm Type
Other
Arm Description
50 g oral glucose tolerance test (OGTT)
Intervention Type
Other
Intervention Name(s)
IIGI+GIP
Intervention Description
Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min) during isoglycemia
Intervention Type
Other
Intervention Name(s)
IIGI+GLP-1
Intervention Description
glucagon-like peptide-1 (1 pmol/kg/min) during isoglycemia
Intervention Type
Other
Intervention Name(s)
IIGI+NaCl (placebo)
Intervention Description
i.v. NaCl during isoglycemia
Intervention Type
Other
Intervention Name(s)
OGTT
Intervention Description
50 g oral glucose tolerance test
Intervention Type
Other
Intervention Name(s)
IIGI+GIP+GLP-1
Intervention Description
i.v infusion of GIP and GLP-1 (4 + 1 pmol/kg/min) during isoglycemia
Primary Outcome Measure Information:
Title
food intake
Description
How much does the participant eat of from the ad libitum meal, measured in gram
Time Frame
250-280 min
Secondary Outcome Measure Information:
Title
hunger
Description
feeling of hunger measured on a visual analogue scale
Time Frame
measured at time 0, 30, 60, 90, 120, 180, 210, 240 min
Title
satiety
Description
feeling of satiety measured on a visual analogue scale
Time Frame
measured at time 0, 30, 60, 90, 120, 180, 210, 240 min
Title
Fullness
Description
feeling of fullness measured on a visual analogue scale
Time Frame
measured at time 0, 30, 60, 90, 120, 180, 210, 240 min
Title
Prospective food consumption
Description
Prospective food consumption measured on a visual analogue scale
Time Frame
measured at time 0, 30, 60, 90, 120, 180, 210, 240 min
Title
resting energy expenditure (REE)
Description
changes in REE measured by a ventilated hood 15 minutes at baseline and 15 minutes at time point 210 min.
Time Frame
-15 to 0 min. and 210 to 225 min.
Title
Insulin
Description
changes in insulin measured in serum
Time Frame
-30, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min
Title
C-peptide level
Description
changes in C-peptide level measured in serum
Time Frame
-30, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min
Title
glucagon levels
Description
changes in glucagon levels measured in plasma
Time Frame
-30, 0, 15, 30, 45, 60, 90, 120, 150, 180, 210, 240 min
Title
Cholesterol and FFA
Description
changes in cholesterol (TAG, Total cholesterol and free fatty acid measured in plasma)
Time Frame
-30, 0, 30, 60, 90, 120, 180, 240 min
Title
C-terminal cross-linked telopeptide of bone collagen (CTX)
Description
changes in level of CTX measured in plasma
Time Frame
-30, 0, 30, 60, 90, 120, 180, 240 min
Title
procollagen type 1 N-terminal propeptide (P1NP)
Description
changes in level of P1NP measured in plasma
Time Frame
-30, 0, 30, 60, 90, 120, 180, 240 min
10. Eligibility
Sex
Male
Minimum Age & Unit of Time
25 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Caucasian men
Age between 25 and 70 years
Body mass index (BMI) between 25 and 40 kg/m2
Exclusion Criteria:
Diabetes or prediabetes (defined as glycated haemoglobin (HbA1c) ≥ 43 mmol/mol)
Anaemia (defined as haemoglobin < 8.3 mmol/l)
Any gastrointestinal disease that may interfere with the endpoint variables
Anorexia, bulimia or binge eating disorder
Allergy or intolerance to ingredients included in the standardised meals
Tobacco smoking
Any regular drug treatment that cannot be discontinued for minimum 18 hours
Any physical or psychological condition that the investigator feels would interfere with trial participation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Natasha C Bergmann, MD
Organizational Affiliation
Center for Diabetesresearch, Gentofte Hospital, University of Copenhagen, Denmark
Official's Role
Principal Investigator
Facility Information:
Facility Name
Center for Diabetesresearch, Gentofte hospital
City
Hellerup
ZIP/Postal Code
2900
Country
Denmark
12. IPD Sharing Statement
Citations:
PubMed Identifier
24174327
Citation
Finan B, Ma T, Ottaway N, Muller TD, Habegger KM, Heppner KM, Kirchner H, Holland J, Hembree J, Raver C, Lockie SH, Smiley DL, Gelfanov V, Yang B, Hofmann S, Bruemmer D, Drucker DJ, Pfluger PT, Perez-Tilve D, Gidda J, Vignati L, Zhang L, Hauptman JB, Lau M, Brecheisen M, Uhles S, Riboulet W, Hainaut E, Sebokova E, Conde-Knape K, Konkar A, DiMarchi RD, Tschop MH. Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans. Sci Transl Med. 2013 Oct 30;5(209):209ra151. doi: 10.1126/scitranslmed.3007218.
Results Reference
background
PubMed Identifier
23684623
Citation
Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013 Jun 4;17(6):819-837. doi: 10.1016/j.cmet.2013.04.008. Epub 2013 May 16.
Results Reference
background
PubMed Identifier
9449682
Citation
Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest. 1998 Feb 1;101(3):515-20. doi: 10.1172/JCI990.
Results Reference
background
PubMed Identifier
25144635
Citation
Nissen A, Christensen M, Knop FK, Vilsboll T, Holst JJ, Hartmann B. Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. J Clin Endocrinol Metab. 2014 Nov;99(11):E2325-9. doi: 10.1210/jc.2014-2547. Epub 2014 Aug 21.
Results Reference
background
PubMed Identifier
30848791
Citation
Bergmann NC, Lund A, Gasbjerg LS, Jorgensen NR, Jessen L, Hartmann B, Holst JJ, Christensen MB, Vilsboll T, Knop FK. Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2953-2960. doi: 10.1210/jc.2019-00008.
Results Reference
derived
PubMed Identifier
30683945
Citation
Bergmann NC, Lund A, Gasbjerg LS, Meessen ECE, Andersen MM, Bergmann S, Hartmann B, Holst JJ, Jessen L, Christensen MB, Vilsboll T, Knop FK. Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. Diabetologia. 2019 Apr;62(4):665-675. doi: 10.1007/s00125-018-4810-0. Epub 2019 Jan 25.
Results Reference
derived
Learn more about this trial
GIP/GLP-1 Co-Activity in Subjects With Obesity: Lowering of Food Intake
We'll reach out to this number within 24 hrs